Nachrichten zur Allergy Therapeutics PLC Aktie

Cavendish has reiterated its 13p target price on Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) after the company posted full-year results that were…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has posted broadly steady annual results and outlined plans that point to a busier year…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has cleared an important hurdle in the early testing of its experimental peanut allergy treatment,…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is evaluating a dual primary listing of its shares on the Main Board…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has given investors something to cheer about. The AIM-listed biotech climbed 3.3% to 8.25p after…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the UK biotechnology company specialising in allergy immunotherapies, has published three new studies in the...…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is gearing up for a busy year, as it reported stable revenue for the…

…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), a biotechnology firm specialising in allergy treatments, is showcasing key research findings at the European...…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive about the...…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is starting to find its feet again, with broker Cavdenidsh noting the financial recovery continues…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) expects sales growth to pick up in the second half of the year and has reiterated…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has reached a key milestone in the clinical development of its peanut allergy vaccine with healthy…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is set to present its latest research at the 2025 American Academy of Allergy, Asthma…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) says the latest publication of phase III trial data provides important validation of its treatment,…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is back on track and growing again after the financial and operational challenges of…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has...…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced encouraging interim findings from its phase I/IIa VLP Peanut PROTECT trial aimed at…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has commenced a phase III trial to test the long-term safety and effectiveness of its…

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) marked a significant milestone after it applied for regulatory approval of its new grass allergy...…

The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market…